Precigen (PGEN) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

PGEN Precigen

Watchlist

1.200
+0.120+11.11%

Close Jan 3 16:00 ET

1.140
-0.060-5.00%

Post 20:01 ET

351.44MMarket Cap-2.22P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

PGEN Stock Surges More Than 40% in a Week: What's Driving the Rally?
Zacks Jan 2 12:30 ET
Precigen Secures $79M Financing for 2025 Launch
TipRanksDec 30, 2024 16:48 ET
Precigen Soars: Biologics License Application Submission For PRGN-2012 Targets First FDA-Approved Recurrent Respiratory Papillomatosis Treatment
Yahoo FinanceDec 30, 2024 12:31 ET
Stifel Maintains Precigen(PGEN.US) With Buy Rating
Moomoo NewsDec 30, 2024 10:32 ET · Ratings
Stifel Thinks Precigen Stock Set to Rebound After Capital Secured, BLA Submitted
TipRanksDec 30, 2024 09:45 ET
Precigen's Strategic Advances and Financial Strength Boost Market Position for PRGN-2012
TipRanksDec 30, 2024 09:45 ET

Comments

HenryRen

Dec 31 13:01

$Precigen (PGEN.US)$
go go go

Share Your Profit/Loss

Jaguar8

Dec 30, 2024 18:59

NEWS TODAY

$Precigen (PGEN.US)$
Precigen Completes Submission of BLA with Request for Priority Review to the FDA for PRGN-2012 for the Treatment of Adults with Recurrent Respiratory Papillomatosis
Monday, 30th December at 7:00 am
– PRGN-2012 has the potential to be the first FDA-approved therapeutic for the treatment of adults with RRP, a rare and devastating chronic disease for which the current standard-of-care is repeated surgeries –
– PRGN-2012 received Breakthrough Therapy Designation fr...

Moomoo AI

Jan 26, 2024 06:18

The company's share price decline mirrors its poor fundamental performance. The recent loss isn't as severe as the 13% annual loss investors endured over the past five years. Key metrics need improvement to generate enthusiasm.

Strong Week for Precigen (NASDAQ:PGEN) Shareholders Doesn't Alleviate Pain of Three-year Loss

Trytosaveabit

Jan 16, 2024 07:10

News

$Precigen (PGEN.US)$Moomoo 24/7· 3 mins ago
Precigen Receives Orphan Drug Designation For PRGN-2012 For Treatment Of Recurrent Respiratory Papillomatosis From The European Commission

Moomoo AI

Dec 28, 2023 04:56

Precigen's declining revenue may necessitate additional funding, potentially diluting existing shareholder stakes. Despite a decrease in cash burn, falling revenue raises apprehension. Investors are urged to fully comprehend business risks prior to investing.

Will Precigen (NASDAQ:PGEN) Spend Its Cash Wisely?

Heat List

Overall

No Data